Brain scans reveal Ketamine's secret against suicidal thoughts?
NCT ID NCT07139106
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study looks at how ketamine, a drug already used for depression, might reduce suicidal thoughts by affecting stress-related brain pathways. Researchers will give 12 adults with major depressive disorder a single ketamine infusion, then use smartphone tracking and PET brain scans to monitor changes. The goal is to understand the biological link between stress and suicidal thinking, not to test ketamine as a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketamine hydrochloride infusion
- What this could lead to
- If successful, this could reveal how ketamine reduces suicidal thoughts, pointing toward better treatments for depression-related suicide risk.
- What could go wrong
- This is a very small early-phase study with only 12 participants, so results may not apply broadly. It focuses on understanding brain mechanisms, not proving a treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 59 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * DSM5 unipolar major depressive episode * Persons of child-bearing potential must agree to use an acceptable method of birth control throughout the study. Exclusion Criteria: * Current or past ketamine abuse or dependence ever (lifetime) * Any medical contraindication to ketamine, including prior ineffective trial of or medically significant adverse reaction to ketamine. * Clinically significant EKG abnormality in terms of ketamine administration (e.g., Ventricular tachycardia, evidence of myocardial ischemia, symptomatic bradycardia, unstable tachycardia, second degree (or greater) AV block). * Lifetime schizophrenia, schizoaffective illness, bipolar disorder, current psychotic depression; mild drug or alcohol use disorder in past 2 months; moderate or severe drug or alcohol use disorder in past 6 months; suicidal ideation with plan and/or intent within 6 months; suicide attempt in the past month. * A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations). * Current or recent use of antidepressants within 14 days or benzodiazepines within 1 day. Use of fluoxetine or other long-acting antidepressant within 6 weeks. * Current or recent use of medications known to affect brain biology of interest such as competing for binding sites of PET tracer within 1 month. * Uncontrolled moderate or severe hypertension (≥160 mmHg systolic or ≥100 mmHg diastolic\[41\]), history of Raynaud's phenomenon, seizures, an open cut, sore, or bone fracture on or near the hands to be used for the cold pressor test. * Use of more than incidental NSAIDs (including aspirin), anti-inflammatories, immune suppressants or other pain medications. * Significant active physical illness, particularly if it may affect the brain biology being studied; including chronic pain syndrome and medically compromising eating disorders or epilepsy. * Lacks capacity to consent * Aggressive behavior that is a significant threat to others such as physically assaultive behavior (in the last month). * Pregnancy, abortion or miscarriage in the previous two months or plans to conceive during the course of study participation. * Currently lactating * Previous head injury with evidence of cognitive impairment. Subjects who endorse a history of prior head trauma and score 1.5 standard deviations below the mean on Trail-making A or B will be excluded from study participation. * Any condition or material in the body that is a contraindication for MRI procedures. * Current, past or anticipated exposure to radiation except if the exposure was at our PET center where the precise exposure is known * ECT within past 6 months * For A-Line Subjects: Unstable relevant medical condition (i.e., condition not adequately stabilized for 3 months). Including bleeding disorders, the need to take medications that affect blood clotting, and certain platelet and hemoglobin cutoffs * Blind or with visual impairment that cannot be corrected with corrective lenses (glasses or contact lenses) * No emergency contact
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway lift teen depression in primary care?
- Can Anti-Inflammatory drugs lift depression that Won't budge?
- A brain stimulation trial aims to rewire the circuit behind depression
- Can pairing ketamine with talk therapy beat depression alone?
- Genetic matchmaking for antidepressants: a global trial puts personalization to the test
- Could a common vitamin lift depression in young people?